44P - Markers of inflammation as prognostic factors for survival in peripheral T-cell lymphoma in Peru. (44P)

Date 08 December 2017
Event ESMO Immuno-Oncology Congress 2017
Session Lunch & Poster Display session
Topics Bioethics, Legal, and Economic Issues
Presenter Denisse Castro
Citation Annals of Oncology (2017) 28 (suppl_11): xi6-xi29. 10.1093/annonc/mdx711
Authors D. Castro1, R. Motta2, B. Beltran2, L. Vasquez2, L. Vera2, R. Salas2, J. Geronimo2
  • 1Lima, Rebagliati Hospital, 41 - Lima/PE
  • 2Lima, Rebagliati Hospital, 051 - Lima/PE



Peripheral T cell lymphoma (PTCL) accounts 15% of NHL, characterized for poor survival. IPI and PIT scores are prognostic factors in survival, but they have limitations. Markers of inflammation: neutrophil/lymphocyte ratio (NLR), monocyte/lymphocyte ratio (MLR), and absolute lymphocyte count/monocyte score (ALC/AMC score), are being evaluated as prognostic tools in different malignancies. The aim of this study is to demonstrate if inflammation markers could be used as prognostic factors in survival in PTCL.


Data of patients diagnosed with PTCL during years 2005-2015 at Rebagliati Hospital was retrospectively reviewed. Patients with cutaneous T-cell lymphoma, CNS lymphoma, ATLL and incomplete data were excluded. OS was determinate with Kaplan-Meier method, comparison of survival curves was made with Log-rank test. Multivariate analysis, prognostic factors for OS were determined using Cox regression model. Statistical evaluations were performed at a significance of 5%.


A total of 68 patients were included. Median age was 61 years, 60.3% were male, 52.9% had ECOG 0-1 and 79% had B symptoms at the time of diagnosis. 58.2% had primary lymph node involvement and the 73.1% had extra-nodal compromise. The 70.6% of patients had clinical stage III-IV and 44.1% had bone marrow infiltration. The 79.2% of patients had a PTCL-NOS subtype, 13.2% Anaplastic, 5.8% NK/T cell Lymphoma and 2.9% an Angioimmunoblastic T- cell lymphoma. OS was 28.4% in 5 years. NLR> 4 was associated with increased risk of mortality (p = 0.001). There was no statistical significance regarding MLR (p = 0.17) and ALC/AMC score (p = 0.49). Multivariate analysis, High-intermediate and High IPI score (HR = 3.02, p = 0.002) were related to NLR> 4 (HR = 2.312, p = 0.016), and High- Intermediate and High PIT score (HR = 2.41, p = 0.001) were related to NLR> 4 (HR = 3,041, p = 0.001).


NLR has proven its prognostic value in patients with PTCL, which is an easily accessible and low-cost tool. This work can serve to address future designs of more efficient scores that allow selection of groups of patients at greater risk and thus lead more individualized therapy.

Clinical trial identification

Legal entity responsible for the study

Denisse Castro MD




All authors have declared no conflicts of interest.